Skip to content

Study · Animal study (in vivo) · mouse · 2010

2 results

NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.

Merenlender-Wagner A, Pikman R, Giladi E, Andrieux A, Gozes I

Peptides22 Apr 2010Cited by 45 (Europe PMC)

PMID20417241 (opens in a new tab)DOI10.1016/j.peptides.2010.04.011 (opens in a new tab)PepBankPUB-20417241
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In STOP heterozygous mice, daily intranasal NAP significantly decreased hyperactivity.

    In plain wordsIn mice with a STOP gene alteration, daily nasal NAP reduced hyperactivity.

    Peptide
    Davunetide
    Outcome
    DecreaseHyperactivity
    Study

    mousen: not reported in source

    STOP heterozygous mice
    Outcome group
    Exercise and physical function · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (mouse).

    Source sentences

    Summary
    Daily intranasal NAP treatment significantly decreased hyperactivity in the STOP+/- mice and protected visual memory.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In STOP heterozygous mice, daily intranasal NAP protected visual memory.

    In plain wordsIn mice with a STOP gene alteration, daily nasal NAP protected visual memory.

    Peptide
    Davunetide
    Outcome
    IncreaseVisual memory
    Study

    mousen: not reported in source

    STOP heterozygous mice
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (mouse).

    Source sentences

    Summary
    Daily intranasal NAP treatment significantly decreased hyperactivity in the STOP+/- mice and protected visual memory.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.